CIK 0001472012 · Non-accelerated filer
Immunome Inc.
Sign in to watch- Ticker
- IMNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770694340
- Phone
- 610-321-3700
- Business address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $334,224
- in 1 filing, $334K under 10b5-1 plans
Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 56 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-23 | Higgins Jack Chief Scientific Officer | Grant or award | +38,250 | 60,250 | ||
| 2026-07-23 | Higgins Jack Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +76,500 | 76,500 | ||
| 2026-07-23 | Horn Kinney CHIEF BUSINESS OFFICER | Grant or award | +31,250 | 31,250 | ||
| 2026-07-23 | Horn Kinney CHIEF BUSINESS OFFICER | Grant or award · Employee Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2026-07-23 | Stoneman Sandra G. CHIEF LEGAL OFFICER & GC | Grant or award | +38,250 | 43,805 | ||
| 2026-07-23 | Stoneman Sandra G. CHIEF LEGAL OFFICER & GC | Grant or award · Employee Stock Option (right to buy) | +76,500 | 76,500 | ||
| 2026-07-23 | SIEGALL CLAY B President and CEO | Grant or award | +180,000 | 870,704 | ||
| 2026-07-23 | SIEGALL CLAY B President and CEO | Grant or award · Employee Stock Option (right to buy) | +360,000 | 360,000 | ||
| 2026-07-07 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise 10b5-1 | +1,092 | $12.92 | $14K | 1,092 |
| 2026-07-07 | Horn Kinney CHIEF BUSINESS OFFICER | Sale 10b5-1 | −1,092 | $25.00 | $27K | 0 |
| 2026-07-07 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,092 | 128,908 | ||
| 2026-07-07 | Barchas Isaac Director | Sale 10b5-1 | −16,906 | $24.20 | $409K | 108,504 |
| 2026-07-06 | Barchas Isaac Director | Sale 10b5-1 | −83,094 | $24.11 | $2.0M | 125,410 |
| 2026-07-02 | Lechleider Robert Chief Medical Officer | Option exercise 10b5-1 | +55,000 | $8.73 | $480K | 70,805 |
| 2026-07-02 | Lechleider Robert Chief Medical Officer | Sale 10b5-1 | −22,714 | $21.95 | $499K | 48,091 |
| 2026-07-02 | Lechleider Robert Chief Medical Officer | Sale 10b5-1 | −16,214 | $22.76 | $369K | 31,877 |
| 2026-07-02 | Lechleider Robert Chief Medical Officer | Sale 10b5-1 | −16,072 | $23.44 | $377K | 15,805 |
| 2026-07-02 | Lechleider Robert Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −55,000 | 290,000 | ||
| 2026-07-02 | Barchas Isaac Director | Sale 10b5-1 | −75,665 | $22.35 | $1.7M | 232,839 |
| 2026-07-02 | Barchas Isaac Director | Sale 10b5-1 | −24,335 | $23.33 | $568K | 208,504 |
Page 2 of 8 · 159 trades